Our commitment to safety communication

Verified safety updates from ongoing ocrelizumab clinical trials and post-marketing experience

As of October 2019, more than 130,000 patients with RMS and PPMS have started ocrelizumab globally1, amounting to a total of more than 140,000 patient-years and more than 500,000 infusions administered.2

> 6,000 patients in clinical trials and open-label extension

> 125,000 patients with post-marketing experience

Our commitment to safety communication

Verified safety updates from ongoing ocrelizumab clinical trials and post-marketing experience

As of October 2019, more than 130,000 patients with RMS and PPMS have started ocrelizumab globally1, amounting to a total of more than 140,000 patient-years and more than 500,000 infusions administered.2

> 6,000 patients in clinical trials and open-label extension

> 125,000 patients with post-marketing experience

Prescribing information

Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.

References

1. Roche data on file: 30 September 2019, post-marketing experience; 31 July 2019, clinical trials data cut-off
2. Roche data on file: 30 September 2019, post-marketing experience; 7 January 2019, clinical trials data cut-off